Why hate on the FDA? Got personal issues?
“Fda approval“ is also a joke” Don‘t know the
difference between approval and clearance?
Better read up on FDA 101 then post. Stupid.
I‘m not in…. But going to buy a little gamble position.
You do know getting FDA approval is haaaard work with many hurdles to beat?!
3 phases over many years….
I understand she does look funny with how the pps developed after approval. But bio sector didn’t go well over all the last couple month.
No personal attack, just my two cents;)
TTOO is just worthless company and pump and dump scheme.Fda approval is also a joke as after releasing it it has been going nowhere but down.
It doesn't benefit the company as a whole. It benefits execs that will dilute and sell this back to the teens. RE: MULN
I told you that ttoo was a scam.
At this point(.15) it absolutely makes no sense to do a RS. What is to be gained? Just to stay on the NASDAQ? What for? Ttoo can make as many deals and sales from the OTC+ as they can from the NASDAQ. Ttoo is now becoming a great takeover target. Great new technology at a bargain basement price. So how does having fewer shares at a higher price really benefit the company. They need to spend the money it takes to go through a RS on sales and advertising.
WTF is “a SDA approval”? I read about an
FDA clearance, but not an “SDA approval”.
Sounds like something drunk trolls say. 😆
Those form 4's keep rolling right on in , I can't help believe that crg is cashing out before the rs shitshow . What a disappointment , another lesson or reason to always take profit . At this point I'd be shocked if they didn't , still on standby tho , ya never know
Yeah, you know all to well going through 2 RS within 90 on MULN, but that didn’t get in your way of buying more. Since you like RS so much, maybe you should perhaps double or triple down on this stock.
YA!!! THAT "FDA" SURE ARE A BUNCH OF JOKESTERS.
BEAM ME UP, SCOTTY!!!!!!!!!!!!!!!!!!
FDA clearances are a joke? What a crock!
Turning FDA actions negative is bear-shit.
Damning bio-techs or Pharma is a hobby?
Guess everything’s wrong w/everything 😆
In this economic environment I am not so sure it is a big deal to remain on the NASDAQ. If you believe a RS WI
In this economic environment I am not sure remaining on the NASDAQ is all that important especially if you believe a RS will bring an end to TTOO. It will take months for sales to be
made and deals signed with the FDA just now giving the green light. Why not just go back to the OTC and let the business grow until it reaches $2.00 and then reapply for the NASDAQ. This way we keep our shares, there is no share restructuring, and TTOO avoids the certain demise of a RS. Just canceling the RS will raise the SP.. It won't be. That long for orders to come in. All of this is really just a timing problem. Being on the NASDAQ is no big deal as there is just as much corruption here as the OTC.
Divide price by fifty.. 50:1 r/s
TTOO could be at .10 by the time the RS takes place, so at 1:100 that would land the price at $10.
But we need to expect it will drift lower after the RS, though you never know for sure.
Just going by the overwhelming majority of stocks that RS. It never seems to end well, especially in the short term.
No,I did not but I can see the stock direction.This is definitely pump and dump scheme.Nobody ever can make money here from existing shareholders.After the R/S this will be diluted and heavily shorted again.Maybe the next R/S after this one coming will be time to invest here.
Great conference, guess that you weren’t listening. '
TTOO is a Scam so you can not be positive or negative either.It is a lottery.
When a lot of inside trades take place, SEC starts to look. Too much trading like this draws the attention of the Feds. So either they are going to produce the product or complaints from shareholders will bring attention. Don't ever think the SEC doesn't read these boards, too.
There's nothing positive here.
I will definitely lose sleep because you don't care about my bs. That really hurts.
Like I give a crap about your bs.
Always negative, never positive.
I prefer to buy low and sell on a
move up. Positively patient. Lol.
Well, your other personality is Bearish, so I don't think you want to talk to him...
And, uh, the other 1%? Crickets there, Hummer?
It must be a miserable thing…all the negative bs.
99 percent of RS fail horrifically... IBIO, AEMD, RGBP were mine.
Then you have a handful that succeeded like the old Priceline that exploded.
Look it up, there is a tiny amount that work.
The ONLY way this works is if the brainless CEO announces contracts the same exact time of the RS, but he won't because he has no bloody idea how to run a business.
Riiiggghhht…stupid bearshit shows the truth here.
TTOO just like the others? Again, always negative.
Not buying it. Not lumping it with others. Cheeses.
Yes they would of figured it out. That they didnt need to split. Just a bunch of dip $hits.
What proof ?Just watch around.Muln,AMC,next what happens after R/S.Most are coming back where started.The market is weak and shorters are winning on any stock.As soon as TTOO does R/S so it will become heavily shorted to push it back where it started again.All existing shareholders will get wiped out.It is the reality.
Why, Hugie? Got any proof? A link? ROTFLMAO
Didn’t think so. Always negative and never a link.
The R/S will not help much.It can go quickly back down where it is now.
If the RS didn't pass, I would probably average down, but there's no way it stays at $1 or more for 10 days before November, so I know John will implement the RS. All he had to do was cancel the RS when he released the FDA approval PR... That's all it would have taken, but he has no functioning brain cells...
That would require brain cells. Sadly, nobody in the company has any as far as how to run a business.
Its not worthless. Nobody wants in with RS looming simple as that. Get rid of RS and this is a dollar in 2 weeks. Eom
Saving lives and improving healthcare by empowering clinicians to effectively treat patients faster
At T2 Biosystems, our mission is to save lives and improve healthcare by empowering clinicians to get patients on the right therapy faster. We come to work every day to solve critical needs in healthcare diagnostics with innovative solutions built on our game-changing T2 Magnetic Resonance (T2MR®) detection technology.
Sepsis claims more lives annually than breast cancer, prostate cancer, and AIDS combined. We’re focused on eradicating deaths due to sepsis by developing tools that help identify the most common and deadly sepsis-causing pathogens faster than ever before. Speed is critical in sepsis management. The faster patients receive effective treatment, the more likely they are to survive and have better outcomes. Better yet, early targeted therapy for bloodstream infections may prevent the progression to sepsis altogether.
Our blood tests provide actionable results in just 3 to 5 hours. The only other way to identify the species-specific diagnosis requires a blood culture, which can take 1 to 5 days or more. Today, T2 Biosystems panels are getting patients on the right therapy faster, and the expedited identification of negative test results allows rapid de-escalation of unneeded therapy. In partnership with hospitals around the world, T2 Biosystems technology is uniquely positioned to strike a huge blow to sepsis and the hundreds of thousands of lives it takes each year.
Our T2Bacteria® and T2Candida® Panels run on the automated T2Dx® Instrument. They are the first and only FDA-cleared blood tests that identify sepsis-causing pathogens without the wait for blood culture. As hospitals continue to adopt our technology, it will represent a paradigm shift that can potentially result in thousands of patients going home to their families instead of the tragic, and potentially avoidable, alternative.
We have an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens
About our name: T2 refers to the measurement of the reaction of water molecules in the presence of magnetic fields. This is what our T2MR technology measures, and it is the inspiration behind our company’s name.
Breakthrough technology enabling direct detection from whole blood
The FDA-cleared T2Dx® Instrument is a fully automated, walk away, clinical multiplex benchtop diagnostic system capable of running tests directly from whole blood.
The benefits of the T2Dx Instrument include
The T2Dx Instrument serves nearly 200 hospitals worldwide and is powered by T2 Magnetic Resonance (T2MR®) technology.
Innovative T2MR®applications currently in development
T2 Biosystems has multiple diagnostic applications in development, all designed to enable further breakthroughs in rapid and accurate therapy for patients. The diagnostics are focused on critical, unmet needs in healthcare, where solutions can serve a dual role of improving patient care while reducing costs.
T2Resistance® Panel: T2 Biosystems has partnered with Allergan and CARB-X to develop panels with additional bacterial species and resistance markers. The T2Resistance Panel detects gram-negative and gram-positive resistance markers and is currently available for research use only (RUO) in the U.S. and CE marked on November 20, 2019.
T2Cauris™ Panel RUO: Direct detection of the emerging superbug Candida auris in patient skin and blood samples and hospital environmental samples are now available for research use only (RUO) assays. The CDC* validated the T2Cauris Panel RUO swab test on patient skin samples and published their 2017 findings in Mycoses.
1. ANSON FUNDS MANAGEMENT LP
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise investment discretion, over the assets of others, in excess of $100 Million. Major institutions include financial holdings companies, banks, insurance companies, mutual fund managers, portfolio managers, self managed pension and endowment funds. The report is limited to equity securities, including common and equivalents, convertible preferred and convertible bonds. The report does not include fixed income, real estate, or cash equivalents. Reports are filed within 45 days after calendar quarter end with the vast majority of updates occurring near the 45th day of the quarter.
About Institutional Holdings
Institutional Holdings information can be used to gauge the volatility and value on the company’s stock.